文献速递炎症性肠病消化道肿瘤与早癌

维得利珠单抗或肿瘤坏死因子拮抗剂使用与既往恶性肿瘤的炎症性肠病患者新发或复发癌症风险:一项回顾性队列研究

Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-13

本回顾性队列研究纳入既往有癌症史的炎症性肠病患者,比较后续启用维得利珠单抗(96例)、抗TNF药物(184例)或无免疫抑制治疗(183例)后新发或复发癌症的风险。中位随访6.2人年期间,维得利珠单抗组18例发生新发(7例)或复发(11例)癌症,发生率为22/1000人年。多变量Cox模型显示,与无免疫抑制治疗相比,维得利珠单抗(HR 1.38,95%CI 0.38-1.36)或抗TNF治疗(HR 1.03,95%CI 0.65-1.64)均未增加新发或复发癌症风险。

要点

  • 既往有癌症史的炎症性肠病患者中,维得利珠单抗组新发或复发癌症发生率为22/1000人年。
  • 多变量分析显示维得利珠单抗(HR 1.38,95%CI 0.38-1.36)未增加新发或复发癌症风险。
  • 抗TNF治疗(HR 1.03,95%CI 0.65-1.64)同样未增加新发或复发癌症风险。

核心结论

  • 在有既往恶性肿瘤的炎症性肠病患者中,维得利珠单抗或肿瘤坏死因子拮抗剂均与新发或复发癌症风险增加无关。

研究设计与样本

  • 回顾性研究纳入既往有当前或既往癌症史的炎症性肠病患者,后续启用维得利珠单抗(96例)、抗TNF药物(184例)或无免疫抑制治疗(183例)。
  • 采用多变量Cox比例风险模型评估癌症诊断后治疗对新发或复发癌症的独立效应。

主要发现

  • 最常见的原发癌症为实体瘤(50%)。
  • 中位随访6.2人年期间,维得利珠单抗组18例发生新发(7例)或复发(11例)癌症,发生率为22/1000人年。
  • 多变量Cox模型调整混杂因素后,与无免疫抑制治疗相比,维得利珠单抗组新发或复发癌症风险无增加(HR 1.38,95%CI 0.38-1.36)。
  • 抗TNF治疗组新发或复发癌症风险亦无增加(HR 1.03,95%CI 0.65-1.64)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment of patients with inflammatory bowel diseases (IBD; Crohn's disease (CD), ulcerative colitis (UC) who have a prior history of cancer pose a unique challenge. The impact of Vedolizumab (VDZ) on the risk of new or recurrent cancers in patients with a previous malignancy is unknown. METHODS: This was a retrospective study of patients with IBD with a history of current or prior cancer who were subsequently initiated on VDZ, tumor necrosis factor α antagonists (anti-TNF), or had no immunosuppressive therapy after the index cancer diagnosis. The occurrence of a new primary cancer or recurrent cancer was ascertained on follow-up. Multivariable Cox-proportional hazard models were used to determine the independent effect of post-cancer treatment on new/recurrent cancer. RESULTS: The study included 96 patients exposed to VDZ after a prior diagnosis of cancer who were compared to 184 and 183 patients exposed to anti-TNF or no immunosuppressive therapy, respectively. The most common primary cancer were solid tumors (50%). Over a median of 6.2 person-years of follow-up, 18 patients on VDZ developed new (7) or recurrent (11) cancer corresponding to a rate of 22 per 1000 person-years after cancer diagnosis. In a multivariable Cox-model, after adjusting for confounders, there was no increase in the risk of new or recurrent cancer with VDZ (HR 1.38 95% CI 0.38 - 1.36) or anti-TNF therapy (HR 1.03, 95% CI 0.65 - 1.64), when compared to no IS. CONCLUSIONS: Neither Vedolizumab nor TNF-antagonists were associated with increased risk of new or recurrent cancers in patients with prior malignancy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vedamurthy A, Gangasani N, Ananthakrishnan AN, et al. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2020. PMID: 33065312. doi:10.1016/j.cgh.2020.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。